论文部分内容阅读
11名心律失常患者,静脉滴注CRL(55 μg/kg/min)60min的峰浓度为3.6±0.6μg/ml。其中8名PVBs患者滴注后26±9 min,PVBs完全消失,血浆中CRL有效浓度为2.6±0.7μg/ml。停滴后血药浓度迅速下降,降至2.0±0.6μg/ml时PVBs又复出现。3名结性早搏病人无效。药代动力学特性表征为单室模型,动力学参数:K=0.032±0.011 min~(-1);t_(1/2)=24±13 min;V_d=0.43±0.19 L/kg。健康志愿者6人,一次iv常咯啉50 mg,继以40μg/kg/min静滴55 min,血药浓度的范围在2.7～3.2μg/ml。对ECG和血压无明显变化。
In 11 patients with arrhythmia, the peak concentration of intravenous infusion of CRL (55 μg / kg / min) at 60 min was 3.6 ± 0.6 μg / ml. PVBs completely disappeared in 8 PVBs patients 26 ± 9 min after instillation, and the effective concentration of CRL in plasma was 2.6 ± 0.7 μg / ml. Drop of blood plasma concentration dropped rapidly, down to 2.0 ± 0.6μg / ml PVBs again appear. 3 patients with premature beats invalid. Pharmacokinetic properties were characterized by a single compartment model with kinetic parameters: K = 0.032 ± 0.011 min -1; t 1/2 (1/2) = 24 ± 13 min; V_d = 0.43 ± 0.19 L / kg. Six healthy volunteers were treated with iv procyrotropin 50 mg once intravenously for 55 min at a dose of 40 μg / kg / min. The plasma concentration ranged from 2.7 to 3.2 μg / ml. No significant changes in ECG and blood pressure.